Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company’s board since May 2017. He brings to Cerecor over two decades of biopharmaceutical experience, having most recently served as Chairman and CEO of Sucampo Pharmaceuticals and led the company’s acquisition by Mallinckrodt Pharmaceuticals for $1.2 billion. Throughout his career, Mr. Greenleaf has demonstrated a track record for creating shareholder value through solid commercial execution and efficient drug development.
{iframe}http://www.digitaljournal.com/pr/3712859{/iframe}